Zerviate

Influenza, House Dust Mite Allergy, Chronic Urticaria + 8 more
Treatment
14 FDA approvals
20 Active Studies for Zerviate

What is Zerviate

CetirizineThe Generic name of this drug
Treatment SummaryCetirizine, also known as Zyrtec, is a medication used to treat allergy symptoms such as sneezing, coughing, nasal congestion, and hives. It is often prescribed for a condition called allergic rhinitis, which affects 15-30% of people in the United States. Allergic rhinitis can cause difficulty with day-to-day activities, missed or unproductive days at work or school, and problems with sleep. Cetirizine is a second-generation H1 antihistamine (SGAH), which means it can block the H1 receptor in the body without causing sed
12 Hour Allergy Dis the brand name
Zerviate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
12 Hour Allergy D
Cetirizine
1988
805

Approved as Treatment by the FDA

Cetirizine, otherwise called 12 Hour Allergy D, is approved by the FDA for 14 uses including Hay Fever and Rhinitis, Allergic .
Hay Fever
Rhinitis, Allergic
Rhinitis, Allergic
Used to treat Respiratory Allergy in combination with Pseudoephedrine
Chronic Urticaria
Grass Allergy
Respiratory Allergy
Used to treat Respiratory Allergy in combination with Pseudoephedrine
Allergy to Tree Pollen
Used to treat Allergy to Tree Pollen in combination with Pseudoephedrine
Chronic Idiopathic Urticaria
Seasonal Allergic Rhinitis
Perennial Allergic Rhinitis (PAR)
Ragweed Allergy
House Dust Mite Allergy
Allergy to Mold
Allergy to Animal Dander

Effectiveness

How Zerviate Affects PatientsCetirizine is a drug used to treat a variety of conditions, including chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis. It has been proven to be effective in treating respiratory allergies, and may also have anti-inflammatory properties that can help with asthma management. Cetirizine works quickly, reducing skin reactions such as wheals and flareups within 20 minutes of taking a single dose. It also helps reduce the time and amount of topical anti-inflammatory formulas needed to treat atopic dermat
How Zerviate works in the bodyCetirizine is a medicine used to treat allergies. It works by blocking the action of a chemical called histamine in your body. Histamine is responsible for many allergy symptoms. Cetirizine has been tested and has shown to be effective in treating allergies and has few side effects. It does not appear to affect other types of receptors in the body, and it does not appear to pass into the brain.

When to interrupt dosage

The prescribed amount of Zerviate is contingent upon the diagnosed condition, including Chronic Idiopathic Urticaria, Allergy to Tree Pollen and Allergy; Dander. The magnitude of dosage deviates, in accordance with the administration technique (e.g. Oral or Syrup) featured in the table below.
Condition
Dosage
Administration
Allergy to Animal Dander
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Grass Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Rhinitis, Allergic
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Influenza
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Ragweed Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Allergy to Mold
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
House Dust Mite Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Chronic Urticaria
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Hay Fever
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Rhinitis, Allergic
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection
Allergy to Tree Pollen
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Tablet, extended release, Tablet, extended release - Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Ophthalmic, Suspension - Oral, Suspension, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Intravenous, Injection

Warnings

Zerviate has two contraindications. It should not be taken together with any of the conditions stipulated in the subsequent table.Zerviate Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Cetirizine may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Cetirizine may interact with Pulse Frequency
There are 20 known major drug interactions with Zerviate.
Common Zerviate Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Mobocertinib.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Cetirizine is combined with Oliceridine.
Zerviate Toxicity & Overdose RiskThe toxic dose of cetirizine in rats is 365mg/kg and in mice is 138mg/kg. In a two-year study, cetirizine was not associated with any cancer-causing effects in rats and mice given dietary doses up to 20mg/kg and 16mg/kg, respectively. Cetirizine was not found to be harmful to fertility in mice given a dose of 64mg/kg. It is categorized as pregnancy category B, meaning it has not been proven to be harmful for pregnant women, but should only be used if necessary. Cetirizine has been
image of a doctor in a lab doing drug, clinical research

Zerviate Novel Uses: Which Conditions Have a Clinical Trial Featuring Zerviate?

38 active clinical trials are being conducted to assess the efficacy of Zerviate in treating Chronic Idiopathic Urticaria, Mold Allergy and Grass Allergy.
Condition
Clinical Trials
Trial Phases
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Rhinitis, Allergic
0 Actively Recruiting
Allergy to Animal Dander
0 Actively Recruiting
Grass Allergy
0 Actively Recruiting
Allergy to Tree Pollen
0 Actively Recruiting
Chronic Urticaria
0 Actively Recruiting
House Dust Mite Allergy
0 Actively Recruiting
Ragweed Allergy
0 Actively Recruiting
Allergy to Mold
0 Actively Recruiting
Rhinitis, Allergic
0 Actively Recruiting
Hay Fever
0 Actively Recruiting

Zerviate Reviews: What are patients saying about Zerviate?

5Patient Review
6/18/2020
Zerviate for Allergic Conjunctivitis
Zerviate is the only thing that has worked for my itchy eyes. I had instant relief and would recommend to anyone else suffering from allergies.
4.3Patient Review
4/14/2021
Zerviate for Allergic Conjunctivitis
I found it effective and took it on several occasions.
4Patient Review
4/14/2021
Zerviate for Allergic Conjunctivitis
This worked for me and I'm glad it did.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zerviate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Zerviate a prescription?

"Zerviate is a prescription medicine that is used to relieve the symptoms of Allergic Conjunctivitis, such as itchiness, redness, and watering of the eyes."

Answered by AI

Is Zerviate over the counter?

"Zerviate (cetirizine) is not available over the counter (OTC). It is only available by prescription from your provider."

Answered by AI

How long can I use Zerviate?

"Is ZERVIATE effective and safe for children to use?

Yes. The safety and effectiveness of ZERVIATE have been evaluated in clinical studies involving children. These studies showed that children experienced no pain when taking ZERVIATE. ZERVIATE is approved for use in children aged 2-17."

Answered by AI

What is Zerviate used for?

"ZERVIATE is a medication for treating itchy eyes that are swollen and irritated due to allergies. instill two drops of ZERVIATE, in each eye, Twice a day."

Answered by AI

Clinical Trials for Zerviate

Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Zerviate clinical trials? We made a collection of clinical trials featuring Zerviate, we think they might fit your search criteria.Go to Trials
Image of Saint Louis University Center for Vaccine Development in St Louis, United States.

A/Texas for Flu

18 - 45
All Sexes
St Louis, MO
This is a research study to understand what happens when a person is infected with influenza ("flu") and how the body controls the infection. Healthy participants (challenge) will be infected with a strain of flu (H3N2), and followed to see what symptoms occur and when they occur. Blood will be drawn and nasopharyngeal (NP) swabs will be collected before participants are infected to understand if having antibodies can protect participants from flu infection or lead to a milder flu illness. Blood will also be drawn and NP swabs collected after participants are infected to understand how and when the body's immune response to flu occurs. Participants will also breathe through a device for virus collection every other day. Participants will be screened during one or more visits and will stay in the inpatient challenge unit for at least 10 days, maybe longer. Participants will complete a FLU PRO Diary Card daily. Blood will be drawn before the challenge and on Days 2, 4, and 8 while in the inpatient unit. NP samples will be taken every day to check for viruses and on certain days, immune responses such as antibodies. If on Day 8 (7 days after the challenge) the participant still has flu virus, medicine will be offered to treat the flu and the participant will be asked to stay in the challenge unit until NP swabs are negative for 2 consecutive days. Once the participant is discharged from the challenge unit, they will be asked to return to the clinic for 3 more visits. At the end of the study will be a final phone call.
Phase 1
Waitlist Available
Saint Louis University Center for Vaccine DevelopmentDaniel F. Hoft, MD, PhD
Image of Emory University Hospital Clinical Research Network in Atlanta, United States.

Influenza Virus for Influenza

18 - 49
All Sexes
Atlanta, GA
This study is designed to help us better understand how the immune system responds to the flu and how flu is transmitted in the environment. The ultimate goal is to develop better vaccines and drugs to protect against or fight the flu. This study will describe how the body's immune system responds to the flu virus during and after infection and how the flu virus is transmitted in the environment. The study will use a flu virus called A/Texas/71/2017 (H3N2), clade 3C3a produced specifically for clinical research in controlled conditions. The study will also assess the safety of the H3N2 influenza challenge in healthy participants. Mild to moderate symptoms are expected based on previous studies with this strain of influenza. Study volunteers will be recruited and screened from the general population of metro Atlanta through advertisements or identified from a database of research participants who have previously agreed to be contacted for future research studies. Participants will provide written consent before study participation. Up to 200 healthy adults, 18-49 years old, will be screened for participation. Eligible participants will take part in the study over 5 months. Enrolled participants will be admitted to Emory University Hospital during which time they will receive the influenza virus in the form of a spray in the nose or exposure to infected participants followed by an 8-12 day inpatient stay for observation. Follow-up outpatient visits will take place at the Hope Clinic of the Emory Vaccine Center. Participants will receive compensation (pro-rated for all visits completed) for their time and effort. There will be no costs to participants as a result of being in the study.
Phase 1
Recruiting
Emory University Hospital Clinical Research Network (+1 Sites)Nadine Rouphael, MD
Have you considered Zerviate clinical trials? We made a collection of clinical trials featuring Zerviate, we think they might fit your search criteria.Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.
Recruiting
Has No Placebo
Loma Linda University Medical Center Troesh Medical CampusElizabeth Johnston Taylor, PhD, FAAN
Image of Research Institute of McGill University Health Centre in Montréal, Canada.

COVID-19 Booster + Flu Vaccine for Immunocompromised People

18+
All Sexes
Montréal, Canada
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2. People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.
Phase 2
Recruiting
Research Institute of McGill University Health Centre (+1 Sites)
Image of Kaiser Permanente Northern California in Pleasanton, United States.

Nudge Communication for Flu Vaccination

18+
All Sexes
Pleasanton, CA
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select populations. However, the potential population-level benefit of influenza vaccination is limited by its uptake. Novel implementation strategies to improve vaccination uptake are needed. KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging communication vs. usual care communication on influenza vaccination uptake among Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Mid Atlantic States (KPMAS) eligible members during the 2024-2025 influenza season.
Waitlist Available
Has No Placebo
Kaiser Permanente Northern California (+1 Sites)Ankeet Bhatt, MD
Image of Rush University in Chicago, United States.

Science Communication Training for Vaccine Hesitancy

18 - 99
All Sexes
Chicago, IL
Dime La VerDAD is an innovative social media capacity-building program that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, "promotores de salud" from the Hispanic community as trusted messengers to debunk vaccination misinformation. The study will leverage existing community relationships in Chicago and a first of its kind misinformation curriculum to debunk misinformation in communities served by participating promotores de salud. Dime La VerDAD (Verify, Debunk, and Disseminate) is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. This mixed methods study will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in infodemiology, 2) evaluate how debunking misinformation is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can lead to changes in opinions and behavior (vaccination rates) about COVID and influenza vaccines among Chicago's predominantly Hispanic communities.
Recruiting
Has No Placebo
Rush University (+3 Sites)Marina DelRios, MD
Have you considered Zerviate clinical trials? We made a collection of clinical trials featuring Zerviate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security